Advertisement
Loading...

BioPorto A/S

THOXFPNK
Healthcare
Medical - Diagnostics & Research
$0.15
$0.00(0.00%)
U.S. Market opens in 12h 35m
Advertisement

BioPorto A/S Fundamental Analysis

BioPorto A/S (THOXF) shows moderate financial fundamentals with a PE ratio of -5.77, profit margin of -2.04%, and ROE of -1.67%. The company generates $0.0B in annual revenue with strong year-over-year growth of 11.16%.

Key Strengths

Cash Position74.24%
PEG Ratio0.10
Current Ratio3.25

Areas of Concern

ROE-1.67%
Operating Margin-2.14%
We analyze THOXF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -280.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-280.1/100

We analyze THOXF's fundamental strength across five key dimensions:

Efficiency Score

Weak

THOXF struggles to generate sufficient returns from assets.

ROA > 10%
-88.29%

Valuation Score

Excellent

THOXF trades at attractive valuation levels.

PE < 25
-5.77
PEG Ratio < 2
0.10

Growth Score

Excellent

THOXF delivers strong and consistent growth momentum.

Revenue Growth > 5%
11.16%
EPS Growth > 10%
11.76%

Financial Health Score

Excellent

THOXF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.12
Current Ratio > 1
3.25

Profitability Score

Weak

THOXF struggles to sustain strong margins.

ROE > 15%
-166.92%
Net Margin ≥ 15%
-2.04%
Positive Free Cash Flow
No

Key Financial Metrics

Is THOXF Expensive or Cheap?

P/E Ratio

THOXF trades at -5.77 times earnings. This suggests potential undervaluation.

-5.77

PEG Ratio

When adjusting for growth, THOXF's PEG of 0.10 indicates potential undervaluation.

0.10

Price to Book

The market values BioPorto A/S at 7.54 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

7.54

EV/EBITDA

Enterprise value stands at -6.27 times EBITDA. This is generally considered low.

-6.27

How Well Does THOXF Make Money?

Net Profit Margin

For every $100 in sales, BioPorto A/S keeps $-2.04 as profit after all expenses.

-2.04%

Operating Margin

Core operations generate -2.14 in profit for every $100 in revenue, before interest and taxes.

-2.14%

ROE

Management delivers $-1.67 in profit for every $100 of shareholder equity.

-1.67%

ROA

BioPorto A/S generates $-88.29 in profit for every $100 in assets, demonstrating efficient asset deployment.

-88.29%

Following the Money - Real Cash Generation

Operating Cash Flow

BioPorto A/S generates limited operating cash flow of $-77.03M, signaling weaker underlying cash strength.

$-77.03M

Free Cash Flow

BioPorto A/S generates weak or negative free cash flow of $-77.03M, restricting financial flexibility.

$-77.03M

FCF Per Share

Each share generates $-0.16 in free cash annually.

$-0.16

FCF Yield

THOXF converts -16.25% of its market value into free cash.

-16.25%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.77

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.10

vs 25 benchmark

P/B Ratio

Price to book value ratio

7.54

vs 25 benchmark

P/S Ratio

Price to sales ratio

11.77

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.12

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.67

vs 25 benchmark

ROA

Return on assets percentage

-0.88

vs 25 benchmark

ROCE

Return on capital employed

-1.29

vs 25 benchmark

How THOXF Stacks Against Its Sector Peers

MetricTHOXF ValueSector AveragePerformance
P/E Ratio-5.7729.20 Better (Cheaper)
ROE-166.92%684.00% Weak
Net Margin-203.89%-52872.00% (disorted) Weak
Debt/Equity0.120.38 Strong (Low Leverage)
Current Ratio3.254.00 Strong Liquidity
ROA-88.29%-19764.00% (disorted) Weak

THOXF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BioPorto A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-31.03%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

47.01%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

14.04%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ